Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.45 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.45 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.43 |
| ▸ | CALCR | P30988 | 7/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569644 | 0.92 | APLNR (0.47) | APLNRPLK1RAMP3CALCROPRD1 | |
| SCHEMBL29569360 | 0.92 | APLNR (0.47) | APLNRPLK1RAMP3CALCROPRD1 | |
| SCHEMBL29569088 | 0.90 | PLK1 (0.49) | APLNRPLK1RAMP3CALCROPRD1 | |
| SCHEMBL29568980 | 0.89 | CXCR4 (0.47) | NMUR2NMUR1APLNRPLK1RAMP3 | |
| SCHEMBL29569376 | 0.89 | CXCR4 (0.47) | NMUR2NMUR1APLNRPLK1RAMP3 | |
| SCHEMBL29889179 | 0.89 | NMUR2 (0.47) | NMUR2NMUR1RAMP3CALCR | |
| SCHEMBL29568619 | 0.88 | APLNR (0.48) | NMUR2NMUR1APLNRPLK1RAMP3 | |
| SCHEMBL29568813 | 0.88 | APLNR (0.48) | NMUR2NMUR1APLNRPLK1RAMP3 | |
| SCHEMBL29569098 | 0.88 | APLNR (0.48) | NMUR2NMUR1APLNRPLK1RAMP3 | |
| SCHEMBL29828754 | 0.87 | TFPI (0.46) | NMUR2NMUR1RAMP3CALCRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215172-B2 | Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2025-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215172-B2 | Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof | EPCAM, CD47, CD69 | NMUR2 3258/4885NMUR1 3208/4885APLNR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.